Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 713
- Registration Number
- NCT00239369
- Locations
- 🇫🇷
Hopital Avicenne, Bobigny, France
🇨🇳Boehringer Ingelheim Investigational Site, Taipei, Taiwan
🇫🇷Mg Recherches, Paris, France
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 311
- Registration Number
- NCT00239408
- Locations
- 🇵🇹
Hospital Garcia de Orta, Almada, Portugal
🇵🇹Unidade Funcional de Infecciologia, Barreiro, Portugal
🇵🇹Hospital Distrital de Faro, Faro, Portugal
Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 109
- Registration Number
- NCT00239486
- Locations
- 🇫🇮
NEURO, Helsinki, Finland
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1185
- Registration Number
- NCT00168779
- Locations
- 🇺🇸
502.476.064 Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States
🇺🇸502.476.003 Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States
🇺🇸502.476.086 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1671
- Registration Number
- NCT00168792
- Locations
- 🇹🇷
Boehringer Ingelheim Investigational Site, Izmir, Turkey
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3494
- Registration Number
- NCT00168818
- Locations
- 🇦🇺
1160.48.06102 Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺1160.48.06104 Ecru, Box Hill, Victoria, Australia
🇦🇺1160.48.06110 Suite 13 level 4, Lismore, New South Wales, Australia
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2101
- Registration Number
- NCT00168805
- Locations
- 🇦🇺
1160.25.06103 Boehringer Ingelheim Investigational Site, Ringwood East, Victoria, Australia
🇦🇹1160.25.04303 Boehringer Ingelheim Investigational Site, Wels, Austria
🇨🇿1160.25.42010 Boehringer Ingelheim Investigational Site, Chomutov, Czech Republic
Tiotropium / Respimat One-Year Study
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 983
- Registration Number
- NCT00168844
- Locations
- 🇬🇧
Boehringer Ingelheim Investigational Site, Torquay, United Kingdom
Tiotropium / Respimat One-Year Study
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1007
- Registration Number
- NCT00168831
- Locations
- 🇦🇹
Baumgartner Hohe Otto Wagner Spital Wien, Wien, Austria
🇬🇧Boehringer Ingelheim Investigational Site, Sunderland, United Kingdom
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 860
- Registration Number
- NCT00168857
- Locations
- 🇲🇽
Fracc. Magallanes, Acapulco Guerrero, Mexico
🇺🇸VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
🇹🇭Pramongkutklao Hospital, Bangkok, Thailand